-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $115

Benzinga·08/11/2026 13:14:05
Listen to the news
Piper Sandler analyst Biren Amin maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $111 to $115.